Seneste forsøg

EudraCT Number: 2021-002818-13

Sponsor Protocol Number: DEALSZ-2021-001

Start Date: 2023-05-12

Sponsor Name: Charité-Universitätsmedizin Berlin

Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit...

Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10040785 - Skin and subcutaneous tissue disorders	10037083	Prurigo	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2021-003398-79

Sponsor Protocol Number: MH21HEM

Start Date: 2023-05-11

Sponsor Name: Princess Máxima Center for pediatric oncology

Full Title: International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + C...

Medical condition: Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signal...

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: NL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-006456-14

Sponsor Protocol Number: K321301

Start Date: 2023-05-10

Sponsor Name: Kowa Research Institute, Inc.

Full Title: A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety ...

Medical condition: In Fuchs endothelial corneal dystrophy (FECD), there is an increased rate of loss of endothelial cells, starting in the centre of Descemet’s membrane and spreading to the periphery, resulting in ex...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10011005	Corneal dystrophy	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) DK (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005245-32

Sponsor Protocol Number: CF102-212LD

Start Date: 2023-05-09

Sponsor Name: CanFite BioPharma Ltd.

Full Title: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Medical condition: Non-Alcoholic Steatohepatitis (NASH) and F1-3 fibrosis.

Disease:	Version	SOC Term	Classification Code	Term	Level
	24.1	10019805 - Hepatobiliary disorders	10053219	Non-alcoholic steatohepatitis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003526-50

Sponsor Protocol Number: HACOL-ACS

Start Date: 2023-05-09

Sponsor Name: Hannover Medical School

Full Title: A prospective, interventional, single-center, single-arm study to assess the effectiveness of Bempedoic acid to achieve LDL-cholesterol targets in patients following ST-elevation or Non-ST-elevatio...

Medical condition: Patients following acute percutaneous coronary intervention for STEMI or NSTEMI insufficiently treated with high-intensity oral lipid lowering therapy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10007541 - Cardiac disorders	10064345	ST segment elevation myocardial infarction	LLT
	20.0	10007541 - Cardiac disorders	10064347	Non ST segment elevation myocardial infarction	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001771-14

Sponsor Protocol Number: SRK-015-004

Start Date: 2023-05-08

Sponsor Name: Scholar Rock, Inc.

Full Title: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigat...

Medical condition: Spinal Muscular Atrophy (SMA)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004850	10041583	Spinal muscular atrophy, unspecified	LLT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: ES (Ongoing) NL (Ongoing) BE (Ongoing) DE (Ongoing) FR (Trial now transitioned) IT (Ongoing) PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003289-18

Sponsor Protocol Number: 219369

Start Date: 2023-05-08

Sponsor Name: GlaxoSmithKline Research & Development Limited

Full Title: A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer

Medical condition: Untreated Stage II/III dMMR/MSI-H locally advanced rectal cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10038049	Rectal cancer stage II	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10038050	Rectal cancer stage III	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) IT (Ongoing) NL (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002470-86

Sponsor Protocol Number: 20190218

Start Date: 2023-05-08

Sponsor Name: Amgen Inc.

Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without...

Medical condition: Overweight and Obesity

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10027433 - Metabolism and nutrition disorders	10029883	Obesity	PT
	24.1	10027433 - Metabolism and nutrition disorders	10033307	Overweight	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) HU (Ongoing) CZ (Ongoing) ES (Ongoing) PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003564-24

Sponsor Protocol Number: JAB-3312-1003

Start Date: 2023-05-05

Sponsor Name: Jacobio Pharmaceuticals Co., Ltd.

Full Title: A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult P...

Medical condition: Advanced Solid Tumors

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065252	Solid tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2022-002650-48

Sponsor Protocol Number: UCDCRC/22/02

Start Date: 2023-05-05

Sponsor Name: University College Dublin

Full Title: The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study)

Medical condition: pre-heart failure with preserved ejection fraction

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004849	10076396	Heart failure with preserved ejection fraction	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Trial now transitioned)

Trial results: (No results available)

Seneste forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner